CycLuc1 |
Catalog No.GC34894
One-Click Copy Product Info
|
CycLuc1 is a synthetic, brain-permeable luciferase substrate, with maximum emission wavelength λmax=604nm.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1247879-16-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
CycLuc1 is a synthetic, brain-permeable luciferase substrate, with maximum emission wavelength λmax=604nm[1]. CycLuc1 can be used for fluorescence imaging analysis in vivo and in vitro characterization studies of mutant luciferase[2].
CycLuc1 has been used to monitor intracranial glioblastoma (GBM) xenograft tumor growth in athymic nude mice at doses of 5-25mg/kg[3]. Intraperitoneal injection of CycLuc1 at 15mg/kg significantly enhanced in vivo bioluminescence imaging of gene expression in the sub-forniceal organ (SFO) or hypothalamic paraventricular nucleus (PVN) within male C57BL/6 mice (8-10 week of age) [4]. After intravenous (iv) injection of CycLuc1 (5mmol/L) in Pathogen-free BALB/c, FVB/N, C57BL/6 and luciferase-expressing transgenic mice (FVB-Tg(CAG-luc,-GFP)L2G85Chco/FathJ), the CycLuc1 signal peaked 4-5 minutes and then produced a stable signal that lasted for more than 60 minutes[5].
References:
[1] Kuchimaru T, Iwano S, Kiyama M, et al. A luciferin analogue generating near-infrared bioluminescence achieves highly sensitive deep-tissue imaging[J]. Nature communications, 2016, 7(1): 11856.
[2] Harwood K R, Mofford D M, Reddy G R, et al. Identification of mutant firefly luciferases that efficiently utilize aminoluciferins[J]. Cell Chemical Biology, 2011, 18(12): 1649-1657.
[3] Gupta S K, Kim M, Marin B M, et al. Synthetic luciferin, CycLuc1, improves bioluminescence imaging for intracranial glioblastoma xenografts[J]. Cancer Research, 2018, 78(13_Supplement): 4112-4112.
[4] Simonyan H, Hurr C, Young C N. A synthetic luciferin improves in vivo bioluminescence imaging of gene expression in cardiovascular brain regions[J]. Physiological Genomics, 2016, 48(10): 762-770.
[5] Evans M S, Chaurette J P, Adams Jr S T, et al. A synthetic luciferin improves bioluminescence imaging in live mice[J]. Nature methods, 2014, 11(4): 393-395.
CycLuc1 based-bioluminescence imaging experiments in living mice:
1.Prepare the CycLuc1 solution:
The 50μmol/L-5mmol/L CycLuc1 working solution is prepared in PBS buffer (pH7.4). After the configuration is completed, filtration sterilization is carried out using a 0.22μm filter membrane.
2. Feeding of mice:
Pathogen-free BALB/c, FVB/N, C57BL/6 and luciferase-expressing transgenic mice (FVB-Tg(CAG-luc,-GFP)L2G85Chco/FathJ) were provided access to food and water ad libitum.
3. Tumor cell inoculation:
Subcutaneous inoculation of mice involved 1×106 luciferase-expressing CMT-64 or DB7 cells suspended in serum-free RPMI medium. The tumors achieved their growth phase over a span of 1–2 weeks before imaging procedures commenced. To establish 4T1 tumors, aliquots of the cells were mixed with the mixture of cells with Matrigel at 1:1 volume ratio (5×105 cells with 50μl serum-free DMEM medium combined with 50μl Matrigel), were implanted into second or fourth mammary fat pads on the left or right sides. Mice received intraperitoneal injections 8 days following engraftment. After administering 100μl of either D-luciferin solution or CycLuc1 at concentrations ranging from 50μmol/L to 5mmol/L the mice received imaging 10 minutes following the injection.
4. Bioluminescence imaging:
Administer isoflurane anesthesia (2% concentration in 1L/min oxygen) to the animals before capturing bioluminescence images using the IVIS Lumina system. The imaging protocol involved capturing images every 2 minutes throughout a 30-minute period, each with 10 seconds of exposure time. Acquire images of the mice at both 1 hour and 2 hours post-injection with each image exposed for 10 seconds. Images were analyzed using Living Image software. Outline regions of interest (ROIs) around each cellular cluster to measure the total photon count within each defined area. All images maintained the same ROI size.
Reference:
[1] Evans M S, Chaurette J P, Adams Jr S T, et al. A synthetic luciferin improves bioluminescence imaging in live mice[J]. Nature methods, 2014, 11(4): 393-395.
| Cas No. | 1247879-16-8 | SDF | |
| Canonical SMILES | O=C([C@@H]1N=C(C2=NC3=CC4=C(NCC4)C=C3S2)SC1)O | ||
| Formula | C13H11N3O2S2 | M.Wt | 305.38 |
| Solubility | DMSO : ≥ 83.33 mg/mL (272.87 mM) | Storage | Store at -20°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2746 mL | 16.373 mL | 32.7461 mL |
| 5 mM | 654.9 μL | 3.2746 mL | 6.5492 mL |
| 10 mM | 327.5 μL | 1.6373 mL | 3.2746 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)